Overview Dividends

(MRNA) Moderna - Ratings and Ratios

Exchange: NASDAQ • Country: United States • Currency: USD • Type: Common Stock • ISIN: US60770K1079

Vaccines, Respiratory, Oncology, Rare-Disease, Therapeutics

Biotechnology
Market Cap in USD: 12,058m

IPO / Inception: 2018-12-07
Return 12m vs S&P 500: -33.7%

EPS (Earnings per Share)

EPS CAGR: -19.60%
EPS Trend: -73.1%

Last SUE: 0.51
Qual. Beats: 0

Revenue

Rev. CAGR: -40.11%
Rev. Trend: -70.4%

Last SUE: 0.45
Qual. Beats: 0

Dividends

Currently no dividends paid

Risk via 5d forecast
Volatility	76.7%
Value at Risk 5%th	111%
Relative Tail Risk	-11.89%

Reward TTM
Sharpe Ratio	-0.22
Alpha	-41.42
CAGR/Max DD	-0.49

Character TTM
Hurst Exponent	0.418
Beta	1.292
Beta Downside	0.840

Drawdowns 3y
Max DD	88.65%
Mean DD	59.34%
Median DD	59.47%

Description: MRNA Moderna January 02, 2026

Moderna, Inc. (NASDAQ: MRNA) is a U.S.-based biotechnology firm that develops messenger-RNA (mRNA) medicines across several therapeutic areas, including respiratory, latent, enteric, public-health, bacterial, oncology, and rare-disease indications. Its product portfolio spans the Spikevax COVID-19 vaccine, RSV and seasonal-influenza candidates, latent-virus vaccines (CMV, EBV, HSV, VZV, HIV), a norovirus vaccine, and a pipeline of bacterial (e.g., Lyme) and oncology (individualized neoantigen, checkpoint-modulating) therapies.

As of FY 2023, Moderna reported approximately $19 billion in total revenue, with mRNA vaccine sales accounting for roughly $14 billion, reflecting a year-over-year growth rate of about 30 % driven by continued COVID-19 booster demand and the rollout of its RSV vaccine. The company’s R&D spend remains high (~ $2.5 billion), underscoring the capital-intensive nature of expanding the mRNA platform into new indications. A key sector driver is the accelerating acceptance of mRNA technology by regulators and payers, which is expanding the addressable market for both infectious-disease vaccines and personalized oncology treatments.

For a deeper quantitative dive into Moderna’s valuation metrics and scenario analysis, you might explore the data and tools available on ValueRay.

Piotroski VR‑10 (Strict, 0-10) 1.5

Net Income (-3.12b TTM) > 0 and > 6% of Revenue (6% = 133.3m TTM)

FCFTA -0.22 (>2.0%) and ΔFCFTA 3.09pp (YES ≥ +1.0pp, WARN ≥ +0.5pp)

NWC/Revenue 221.4% (prev 147.6%; Δ 73.74pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp)

CFO/TA -0.16 (>3.0%) and CFO -1.98b > Net Income -3.12b (YES >=105%, WARN >=100%)

NO Net Debt/EBITDA fails (EBITDA <= 0)

Current Ratio 3.93 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active)

Outstanding Shares last Quarter (390.0m) change vs 12m ago -2.26% (target <= -2.0% for YES)

Gross Margin 11.93% (prev 67.29%; Δ -55.35pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0)

Asset Turnover 15.90% (prev 31.99%; Δ -16.09pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0)

Interest Coverage Ratio -393.1 (EBITDA TTM -2.94b / Interest Expense TTM 8.00m) >= 6 (WARN >= 3)

Altman Z'' 6.33

(A) 0.41 = (Total Current Assets 6.60b - Total Current Liabilities 1.68b) / Total Assets 12.13b

(B) 0.66 = Retained Earnings (Balance) 8.05b / Total Assets 12.13b

(D) 2.88 = Book Value of Equity 8.08b / Total Liabilities 2.81b

Total Rating: 6.33 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D)

ValueRay F-Score (Strict, 0-100) 22.55

1. Piotroski 1.50pt

2. FCF Yield -32.13%

3. FCF Margin data missing

4. Debt/Equity 0.08

5. Debt/Ebitda 0.14

6. ROIC - WACC (= -44.12)%

7. RoE -31.40%

8. Rev. Trend -70.39%

9. EPS Trend -73.09%

What is the price of MRNA shares?

As of January 09, 2026, the stock is trading at USD 33.86 with a total of 9,194,183 shares traded.
Over the past week, the price has changed by +9.72%, over one month by +21.06%, over three months by +21.28% and over the past year by -21.57%.

Is MRNA a buy, sell or hold?

Moderna has received a consensus analysts rating of 3.22. Therefor, it is recommend to hold MRNA.

Strong Buy: 5
Buy: 1
Hold: 17
Sell: 3
Strong Sell: 1

What are the forecasts/targets for the MRNA price?

Issuer	Target	Up/Down from current
Wallstreet Target Price	36.8	8.5%
Analysts Target Price	36.8	8.5%
ValueRay Target Price	25.7	-24.1%

MRNA Fundamental Data Overview January 05, 2026

P/E Forward = 32.4675
P/S = 5.4023
P/B = 1.2924
Beta = 1.113
Revenue TTM = 2.22b USD
EBIT TTM = -3.15b USD
EBITDA TTM = -2.94b USD
Long Term Debt = 734.0m USD (from capitalLeaseObligations, last quarter)
Short Term Debt = 48.0m USD (from shortTermDebt, last quarter)
Debt = 734.0m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = -399.0m USD (from netDebt column, last quarter)
Enterprise Value = 8.29b USD (12.06b + Debt 734.0m - CCE 4.50b)
Interest Coverage Ratio = -393.1 (Ebit TTM -3.15b / Interest Expense TTM 8.00m)
FCF Yield = -32.13% (FCF TTM -2.66b / Enterprise Value 8.29b)
FCF Margin = -119.9% (FCF TTM -2.66b / Revenue TTM 2.22b)
Net Margin = -140.3% (Net Income TTM -3.12b / Revenue TTM 2.22b)
Gross Margin = 11.93% ((Revenue TTM 2.22b - Cost of Revenue TTM 1.96b) / Revenue TTM)
Gross Margin QoQ = 0.79% (prev 16.20%)
Tobins Q-Ratio = 0.68 (Enterprise Value 8.29b / Total Assets 12.13b)
Interest Expense / Debt = 1.09% (Interest Expense 8.00m / Debt 734.0m)
Taxrate = -6.95% (negative due to tax credits) (13.0m / -187.0m)
NOPAT = -3.36b (EBIT -3.15b * (1 - -6.95%)) [loss with tax shield] [negative tax rate / tax credits]
Current Ratio = 3.93 (Total Current Assets 6.60b / Total Current Liabilities 1.68b)
Debt / Equity = 0.08 (Debt 734.0m / totalStockholderEquity, last quarter 9.33b)
Debt / EBITDA = 0.14 (negative EBITDA) (Net Debt -399.0m / EBITDA -2.94b)
Debt / FCF = 0.15 (negative FCF - burning cash) (Net Debt -399.0m / FCF TTM -2.66b)
Total Stockholder Equity = 9.92b (last 4 quarters mean from totalStockholderEquity)
RoA = -22.31% (Net Income -3.12b / Total Assets 12.13b)
RoE = -31.40% (Net Income TTM -3.12b / Total Stockholder Equity 9.92b)
RoCE = -29.51% (EBIT -3.15b / Capital Employed (Equity 9.92b + L.T.Debt 734.0m))
RoIC = -33.89% (negative operating profit) (NOPAT -3.36b / Invested Capital 9.92b)
WACC = 10.23% (E(12.06b)/V(12.79b) * Re(10.78%) + D(734.0m)/V(12.79b) * Rd(1.09%) * (1-Tc(-0.07)))
Discount Rate = 10.78% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: -33.33 | Cagr: -0.63%
Fair Price DCF = unknown (Cash Flow -2.66b)
EPS Correlation: -73.09 | EPS CAGR: -19.60% | SUE: 0.51 | # QB: 0
Revenue Correlation: -70.39 | Revenue CAGR: -40.11% | SUE: 0.45 | # QB: 0
EPS next Quarter (2026-03-31): EPS=-2.32 | Chg30d=+0.046 | Revisions Net=+2 | Analysts=5
EPS next Year (2026-12-31): EPS=-7.05 | Chg30d=-0.015 | Revisions Net=+9 | Growth EPS=+12.6% | Growth Revenue=+2.3%

Additional Sources for MRNA Stock

News: Wall Street Journal | Benzinga | Yahoo Finance
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle